WO200153312 Comparison

ID AAM39781 standard; Protein; 772 AA.
XX
AC AAM39781;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 2926.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR N-PSDB; AAI58937.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Example 4; SEQ ID NO 2926; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic

CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 772 AA;

Query Match 100.0%; Score 4037; DB 22; Length 772;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 772; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 MRLSSLLALLRPALPLILGLSLGCSLSLLRVSWIQGEGEDPCVEAVGERGGPQNPDSRAR 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 mrlssllallrpalplilglslgcslsllrvswiqgegedpcveavgerggpqnpdsrar 60

Qy      61 LDQSDEDFKPRIVPYYRDPNKPYKKVLRTRYIQTELGSRERLLVAVLTSRATLSTLAVAV 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 ldqsdedfkprivpyyrdpnkpykkvlrtryiqtelgsrerllvavltsratlstlavav 120

Qy     121 NRTVAHHFPRLLYFTGQRGARAPAGMQVVSHGDERPAWLMSETLRHLHTHFGADYDWFFI 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 nrtvahhfprllyftgqrgarapagmqvvshgderpawlmsetlrhlhthfgadydwffi 180

Qy     181 MQDDTYVQAPRLAALAGHLSINQDLYLGRAEEFIGAGEQARYCHGGFGYLLSRSLLLRLR 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 mqddtyvqaprlaalaghlsinqdlylgraeefigageqarychggfgyllsrslllrlr 240

Qy     241 PHLDGCRGDILSARPDEWLGRCLIDSLGVGCVSQHQGQQYRSFELAKNRDPEKEGSSAFL 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 phldgcrgdilsarpdewlgrclidslgvgcvsqhqgqqyrsfelaknrdpekegssafl 300

Qy     301 SAFAVHPVSEGTLMYRLHKRFSALELERAYSEIEQLQAQIRNLTVLTPEGEAGLSWPVGL 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 safavhpvsegtlmyrlhkrfsalelerayseieqlqaqirnltvltpegeaglswpvgl 360

Qy     361 PAPFTPHSRFEVLGWDYFTEQHTFSCADGAPKCPLQGASRADVGDALETALEQLNRRYQP 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     361 papftphsrfevlgwdyfteqhtfscadgapkcplqgasradvgdaletaleqlnrryqp 420

Qy     421 RLRFQKQRLLNGYRRFDPARGMEYTLDLLLECVTQRGHRRALARRVSLLRPLSRVEILPM 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 rlrfqkqrllngyrrfdpargmeytldlllecvtqrghrralarrvsllrplsrveilpm 480

Qy     481 PYVTEATRVQLVLPLLVAEAAAAPAFLEAFAANVLEPREHALLTLLLVYGPREGGRGAPD 540
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 pyvteatrvqlvlpllvaeaaaapafleafaanvleprehalltlllvygpreggrgapd 540

Qy     541 PFLGVKAAAAELERRYPGTRLAWLAVRAEAPSQVRLMDVVSKKHPVDTLFFLTTVWTRPG 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 pflgvkaaaaelerrypgtrlawlavraeapsqvrlmdvvskkhpvdtlffllttvwtrpg 600

Qy     601 PEVLNRCRMNAISGWQAFFPVHFQEFNPALSPQRSPPGPPGAGPDPPSPPGADPSRGAPI 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 pevlnrcrmnaisgwqaffpvhfqefnpalspqrsppgppgagpdppsppgadpsrgapi 660
```

```
Qy     661 GGRFDRQASAEGCFYNADYLAARARLAGELAGQEEEEALEGLEVMDVFLRFSGLHLFRAV 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 ggrfdrqasaegcfynadylaararlagelagqeeeealeglevmdvflrfsglhlfrav 720

Qy     721 EPGLVQKFSLRDCSPRLSEELYHRCRLSNLEGLGGRAQLAMALFEQEQANST 772
           |||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 epglvqkfslrdcsprlseelyhrcrlsnleglggraqlamalfeqeqanst 772


RESULT   2
AAB80269
ID   AAB80269 standard; Protein; 772 AA.
XX
AC   AAB80269;
XX
DT   24-APR-2001  (first entry)
XX
DE   Human PRO339 protein.
XX
KW   Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;
KW   antiparkinsonian nootropic; neuroprotective; vulnerary; cardiant;
KW   antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;
KW   antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes;
KW   ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
KW   ischaemia; inflammation.
XX
OS   Homo sapiens.
XX
PN   WO200104311-A1.
XX
PD   18-JAN-2001.
XX
PF   22-FEB-2000; 2000WO-US04414.
XX
PR   07-JUL-1999;   99US-0143048.
PR   26-JUL-1999;   99US-0145698.
PR   28-JUL-1999;   99US-0146222.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   05-JAN-2000;   99WO-US00219.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Botstein D,  Desnoyers L,  Eaton DL,  Ferrara N;
PI   Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Grimaldi CJ,  Gurney AL,  Hillan KJ,  Kljavin IJ;
PI   Mather JP,  Pan J,  Paoni NF,  Roy MA,  Stewart TA,  Tumas D;
PI   Williams PM,  Wood WI;
XX
```

ID AAI58937 standard; cDNA; 2710 BP.
AC AAI58937;
DT 22-OCT-2001 (first entry)
DE Human polynucleotide SEQ ID NO 1140.
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia; ss.
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR P-PSDB; AAM39781.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Claim 1; SEQ ID NO 1140; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 2710 BP; 506 A; 821 C; 824 G; 559 T; 0 other;

  Query Match   96.5%; Score 2692; DB 22; Length 2710;
  Best Local Similarity   100.0%; Pred. No. 0;
  Matches 2692; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   98 gggggttagttccgacaccttcacagttgaagagcaggcagaaggagttgtgaagacagg 157



```
Qy   1118 cctcattgactctctgggcgtcggctgtgtctcacagcaccaggggcagcagtatcgctc 1177
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1027 cctcattgactctctgggcgtcggctgtgtctcacagcaccaggggcagcagtatcgctc 1086

Qy   1178 atttgaactggccaaaaatagggaccctgagaaggaagggagctcggctttcctgagtgc 1237
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1087 atttgaactggccaaaaatagggaccctgagaaggaagggagctcggctttcctgagtgc 1146

Qy   1238 cttcgccgtgcaccctgtctccgaaggtaccctcatgtaccggctccacaaacgcttcag 1297
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1147 cttcgccgtgcaccctgtctccgaaggtaccctcatgtaccggctccacaaacgcttcag 1206

Qy   1298 cgctctggagttggagcgggcttacagtgaaatagaacaactgcaggctcagatccggaa 1357
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1207 cgctctggagttggagcgggcttacagtgaaatagaacaactgcaggctcagatccggaa 1266

Qy   1358 cctgaccgtgctgacccccgaaggggaggcagggctgagctggcccgttgggctccctgc 1417
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1267 cctgaccgtgctgacccccgaaggggaggcagggctgagctggcccgttgggctccctgc 1326

Qy   1418 tcctttcacaccacactctcgctttgaggtgctgggctgggactacttcacagagcagca 1477
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1327 tcctttcacaccacactctcgctttgaggtgctgggctgggactacttcacagagcagca 1386

Qy   1478 caccttctcctgtgcagatggggctcccaagtgcccactacagggggctagcagggcgga 1537
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1387 caccttctcctgtgcagatggggctcccaagtgcccactacagggggctagcagggcgga 1446

Qy   1538 cgtgggtgatgcgttggagactgccctggagcagctcaatcggcgctatcagccccgcct 1597
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1447 cgtgggtgatgcgttggagactgccctggagcagctcaatcggcgctatcagccccgcct 1506

Qy   1598 gcgcttccagaagcagcgactgctcaacggctatcggcgcttcgacccagcacggggcat 1657
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1507 gcgcttccagaagcagcgactgctcaacggctatcggcgcttcgacccagcacggggcat 1566

Qy   1658 ggagtacaccctggacctgctgttggaatgtgtgacacagcgtgggcaccggcgggccct 1717
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1567 ggagtacaccctggacctgctgttggaatgtgtgacacagcgtgggcaccggcgggccct 1626

Qy   1718 ggctcgcagggtcagcctgctgcggccactgagccgggtggaaatcctacctatgcccta 1777
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1627 ggctcgcagggtcagcctgctgcggccactgagccgggtggaaatcctacctatgcccta 1686

Qy   1778 tgtcactgaggccacccgagtgcagctggtgctgccactcctggtggctgaagctgctgc 1837
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1687 tgtcactgaggccacccgagtgcagctggtgctgccactcctggtggctgaagctgctgc 1746

Qy   1838 agccccggctttcctcgaggcgtttgcagccaatgtcctggagccacgagaacatgcatt 1897
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1747 agccccggctttcctcgaggcgtttgcagccaatgtcctggagccacgagaacatgcatt 1806

Qy   1898 gctcaccctgttgctggtctacgggccacgagaaggtggccgtggagctccagacccatt 1957
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1807 gctcaccctgttgctggtctacgggccacgagaaggtggccgtggagctccagacccatt 1866

Qy   1958 tcttggggtgaaggctgcagcagcggagttagagcgacggtaccctgggacgaggctggc 2017
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1867 tcttggggtgaaggctgcagcagcggagttagagcgacggtaccctgggacgaggctggc 1926

Qy   2018 ctggctcgctgtgcgagcagaggccccttcccaggtgcgactcatggacgtggtctcgaa 2077
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1927 ctggctcgctgtgcgagcagaggccccttcccaggtgcgactcatggacgtggtctcgaa 1986

Qy   2078 gaagcaccctgtggacactctcttcttccttaccaccgtgtggacaaggcctgggcccga 2137
```


Db 1987 gaagcaccctgtggacactctcttcttccttaccaccgtgtggacaaggcctgggcccga 2046
Qy 2138 agtcctcaaccgctgtcgcatgaatgccatctctggctggcaggccttctttccagtcca 2197
Db 2047 agtcctcaaccgctgtcgcatgaatgccatctctggctggcaggccttctttccagtcca 2106
Qy 2198 tttccaggagttcaatcctgccctgtcaccacagagatcacccccagggcccccgggggc 2257
Db 2107 tttccaggagttcaatcctgccctgtcaccacagagatcacccccagggcccccgggggc 2166
Qy 2258 tggccctgacccccctccccctcctggtgctgacccctcccgggggggctcctataggggg 2317
Db 2167 tggccctgacccccctccccctcctggtgctgacccctcccgggggggctcctataggggg 2226
Qy 2318 gagatttgaccggcaggcttctgcggagggctgcttctacaacgctgactacctggcggc 2377
Db 2227 gagatttgaccggcaggcttctgcggagggctgcttctacaacgctgactacctggcggc 2286
Qy 2378 ccgagcccggctggcaggtgaactggcaggccaggaagaggaggaagccctggaggggct 2437
Db 2287 ccgagcccggctggcaggtgaactggcaggccaggaagaggaggaagccctggaggggct 2346
Qy 2438 ggaggtgatggatgttttcctccggttctcagggctccacctctttcgggccgtagagcc 2497
Db 2347 ggaggtgatggatgttttcctccggttctcagggctccacctctttcgggccgtagagcc 2406
Qy 2498 agggctggtgcagaagttctccctgcgagactgcagcccacggctcagtgaagaactcta 2557
Db 2407 agggctggtgcagaagttctccctgcgagactgcagcccacggctcagtgaagaactcta 2466
Qy 2558 ccaccgctgccgcctcagcaacctggaggggctaggggggccgtgcccagctggctatggc 2617
Db 2467 ccaccgctgccgcctcagcaacctggaggggctaggggggccgtgcccagctggctatggc 2526
Qy 2618 tctctttgagcaggagcaggccaatagcacttagcccgcctgggggccctaacctcatta 2677
Db 2527 tctctttgagcaggagcaggccaatagcacttagcccgcctgggggccctaacctcatta 2586
Qy 2678 cctttcctttgtctgcctcagccccaggaagggcaaggcaagatggtggacagatagaga 2737
Db 2587 cctttcctttgtctgcctcagccccaggaagggcaaggcaagatggtggacagatagaga 2646
Qy 2738 attgttgctgtatttttaaatatgaaaatgttattaaacatgtcttctgcc 2789
Db 2647 attgttgctgtatttttaaatatgaaaatgttattaaacatgtcttctgcc 2698